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Pediatric ALL is the most common type of malignancy in children with 15% bearing 
markers for the T-lineage (T-ALL) and 20% of T-ALL patients still suffering disease 
relapse. Many genes are implicated in T-ALL disease, including Notch, and Notch 
mutations have been identified in a majority of T-ALL patients
1
. Patients with T-ALL 
relapse with disease usually in the central nervous system (CNS)
2
. Despite the use of 
intrathecal therapy and cranial radiation, successful management of CNS disease 
continues to be problematic in T-ALL
3
. Few molecules are known to be associated with 
T-ALL CNS disease including CCR7, a chemokine receptor normally expressed on naïve 
T cells
4
. CXCR4 has also recently been shown to play a role in T-ALL initiation and 
progression
5-7
. The involvement of chemokine receptors as well as other molecules 
regulating cell motility suggests that regulation of T-ALL cell migration is likely to play 
an important role in T-ALL. 
Cell signaling molecules that drive normal T cell proliferation such as PKCθ can regulate 
T-ALL
8
. PKCθ activates CARMA1 (also known as CARD11) bringing together Bcl10 and 
MALT1 leading to NF-κB activation9. While higher expression of CARMA1 has been seen 
in a small subset of T-ALL patients, little is known about how CARMA1 might regulate T-
ALL
10
. To study the potential role of CARMA1 in T-ALL disease, we used shRNA to 
knock down CARMA1 expression in the human CEM T-ALL cell line expressing 
luciferase and GFP (called CARMA1KD), with the level of knockdown approximately 
50% (Supp Fig. 1A). We transferred the CARMA1KD CEM cells into the 
immunodeficient NOD.Cg-Prkdc
scid
 Il2rg
tm1Wjl
/SzJ IL2RG (NSG) mice. Animals receiving 
CARMA1KD T-ALL cells survived significantly longer than animals receiving parental 
CEM cells (Fig. 1A). We also used a Notch1-∆E induced mouse T-ALL model in which 
hematopoietic precursors from WT C57Bl/6 (called WT/WT
 Notch1∆E
; labeled WT) or 
CARMA1-/- (WT/CARMA1-/-
 Notch1∆E
; labeled CARMA1KO) animals were transduced 
with Notch1∆E-GFP and develop T-ALL. Like the xenograft model, we found that 
WT/CARMA1-/-
 Notch1∆E
 (CARMA1KO) animals survived significantly longer than 
WT/WT
 Notch1∆E
 (WT)(Fig.1B).  
We then asked whether CARMA1 is also involved in human T-ALL disease. Using 
microarray analyses from patient T-ALL cells, we compared CARMA1 expression in 
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bone marrow (BM) cells from T-ALL patients with BM cells from a non-leukemia 
control population. CARMA1 expression was significantly higher in the T-ALL patients 
cells compared to non-leukemic cells (Fig. 1C) and other tumor types, including lung, 
liver, and breast (Fig 1D). These results, along with the animal models, demonstrate that 
CARMA1 is an important regulator of T-ALL disease.  
We assessed proliferation of CARMA1KD cells compared to parental CEM T-ALL cells. 
Surprisingly, we found that CARMA1KD showed no difference in basal in vitro 
proliferation measured by cell growth in culture (Supp Fig. 1B) or baseline T-ALL cell 
apoptosis measured by Annexin V staining (Supp Fig. 1C) compared to parental CEM T-
ALL cells. We also assessed tumor growth using in vivo bioluminescent luciferase imaging 
of CEM cells. Animals that received parental CEM cells showed a higher T-ALL tumor 
load than animals receiving CARMA1KD CEM cells at weeks 1, 2, and 3 (Supp Fig. 2A, 
B). We examined T-ALL cell accumulation in specific tissues using anti-human CD45 and 
GFP expression to identify CEM cells by flow cytometry. CARMA1KD CEM cells were 
significantly decreased in the liver, but we saw no difference in the BM or in spleens 
between parental and CARMA1KD CEMs (Fig. 1E). Using the NOTCH-induced T-ALL 
model, we found that CARMA1-/- T-ALL cells accumulated less in lymph node, but not in 
BM, spleen, or liver (Supp Fig. 2C).  
Our previous results suggested CARMA1 may regulate differential migration patterns to 
specific organs. We used the transwell migration assay to compare the migration of 
parental and CARMA1KD CEM cells in vitro. We assessed T-ALL cell migration towards 
CCL21, the ligand for CCR7 and found that CARMA1KD CEM cells showed a significant 
decrease in migration to CCL21 and LFA-1 ligand ICAM-1 compared to parental CEM 
cells (Fig. 2A). CCR7 has been shown to regulate T-ALL migration specifically to the 
CNS
4
. Using the CEM xenograft model, we could detect the presence of parental CEM 
cells in both the calvarial BM (indicated by *) as well as the meninges of the CNS (arrows, 
Fig. 2B) 
11
. In contrast, animals receiving CARMA1KD CEM cells showed little to no 
accumulation in the meninges, but still showed accumulation in the BM. We measured the 
total area of meningeal T-ALL infiltrate in 4 coronal sections per mouse and parental CEM 
cells showed higher levels of cell infiltration compared with CARMA1KD CEM cells 
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(Supp Table 1A). We also analyzed CNS infiltration of T-ALL cells in the NOTCH model 
of T-ALL and found similar results to the xenograft model (Supp Fig. 3, Supp Table 1B). 
These data show that CARMA1 expression in T-ALL cells leads to an increase in T-ALL 
cell infiltration into the CNS. 
We then evaluated CARMA1 expression in a cohort of T-ALL patients who initially 
presented with T-ALL cells in the CNS versus patients who showed no CNS disease at 
time of diagnosis. T-ALL patients with CNS involvement showed significantly higher 
expression of both CARMA1 probes in the microarray compared to patients with no CNS 
involvement (Fig. 2C). These results suggest that CARMA1 may specifically regulate T-
ALL cell migration to the CNS. 
In this study, we show that CARMA1 is a novel regulator of T-ALL disease in animal 
models as well as data from T-ALL patients. CARMA1 expression is associated with 
increased T-ALL disease severity as well as leukemia cell accumulation in the CNS. Many 
studies, including whole genome studies, have identified novel regulators of T-ALL 
disease
12
. A previous study showed that CARMA1 is upregulated in a small group of T-
ALL patients
10
 but did not find a specific role for CARMA1 in CNS disease. Only a few 
molecules, including chemokine receptors CCR7 and CXCR4 have been specifically 
shown to be involved in CNS disease in T-ALL
4, 5
. We find that animals with CARMA1-/- 
T-ALL show similar survival advantage to CCR7-/- T-ALL (Supp Fig. 4). We also find 
that CARMA1 colocalizes with CCR7 (Supp Fig. 5) and CARMA1KD cells show 
decreased migration to the CCR7 ligand CCL21 in vitro. While some of our results 
suggests that CARMA1 affects migration of T-ALL cells directly downstream of CCR7, it 
is also possible that CARMA1 and CCR7 independently regulate T-ALL cell migration. In 
T cells, CXCR4 has also been colocalized with ZAP70, suggesting that crosstalk between 
chemokine receptors and intracellular signaling pathways such as CCR7 and CARMA1 
may act both in normal and leukemic cells to regulate cell migration
13
. 
In normal T cells, TCR activation activates PKCθ phosphorylation of CARMA1, leading to 
NF-kB activation
9
. We previously showed that PKCθ and CARMA1 regulate naïve T cell 
migration
14, 15
 and PKCθ has been shown to play a role in T-ALL8. We find that animals 
receiving PKCθKD CEM cells show similar survival to those receiving parental CEM cells 
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(Supp Fig. 6A and B). This suggests that unlike naïve T cells, in which PKCθ activates 
CARMA1, T-ALL cells may activate CARMA1 independently of PKCθ. CARMA1 may 
be aberrantly upregulated in T-ALL, leading to disease progression and migration of 
leukemic cells to the CNS. In the future, inhibitors of CARMA1 or pathways that lead to 
CARMA1 activation may prove therapeutically useful in controlling CNS disease in T-
ALL.  
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Figure legends: 
Figure 1: CARMA1 expression exacerbates T-ALL disease. (A) Survival curves of NSG 
recipients xenografted with parental (n=22) or CARMA1KD (n=25) CEM cells. (B) Lin
-
 
cells from bone marrow of C57Bl/6 and CARMA1-/- mice were transfected with 
Notch1∆E-GFP and transferred into irradiated B6.LY5.1 animals. Survival curves for 
WT/WT
 Notch1∆E
 (labeled WT) animals (n=12) and WT/CARMA1-/-
 Notch1∆E
 animals 
(labeled CARMA1 KO) (n=11) are shown. For (A) and (B), p-values were determined 
using the Mantel-Cox test. (C) Data from non-leukemic bone marrow and T-ALL patient 
bone marrow from GEO accession # GSE13204 were analyzed using the indicated 
CARMA1 probes. (D) Data from CCLE were analyzed for CARMA1 as shown for 
indicated solid tumor cell lines and T-ALL. For comparisons in (C) and (D), the number of 
patients in each group is shown by n and p-values calculated using the Mann-Whitney 
Wilcoxon test and exact p values shown. (E) Specified organs were processed from animals 
receiving parental or CARMA1KD cells at week 3 and GFP+ CEM cells were enumerated. 
P-values shown used the Student’s t-test.  
Figure 2: CARMA1 regulates T-ALL cell migration to the CNS. (A) Parental and 
CARMA1KD CEM cells were assayed for migration by transwell assay towards CCL21, 
ICAM1, or CCL21+ICAM1. P-values shown were calculated with the Student’s t-test. (B) 
Heads of xenotransplanted animals with parental or CARMA1KD CEM cells and 
processed for H&E (in Methods). Images of sections through skull and meninges of two 
representative mice (of 4) and stained for H&E (left hand panel) or anti-human CD45 (right 
hand panel). Meningeal infiltration indicated by thick arrow and bone marrow by *. Scale 
bar represents 100µm. (C) Data from study 9404 GEO accession # GSE14615 were 
analyzed for indicated CARMA1 probes. For all comparisons, the number of patients in 
each group is shown by n and p-values calculated using the Mann-Whitney Wilcoxon test 
and exact p values shown. 
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Supplemental Figure Legends 
Supplemental Figure 1: CARMA1 does not regulate basal proliferation or apoptosis of 
CEM cells. (A) Parental and CARMA1KD CEM cells were assayed for CARMA1 mRNA 
(left) and protein (right). (B,C) Parental and CARMA1KD CEM cells were assayed for (B) 
proliferation by cell counting over 4 days, (C) apoptosis by Annexin V and DAPI staining. 
Quantification on (C) shown in right panel was done by enumerating Annexin V+DAPI+ 
population and shows an average of 3 replicates.  
Supplemental Figure 2: CARMA1 expression increases T-ALL tumor burden and T-ALL 
cell accumulation in specific organs. NSG animals xenografted with parental or 
CARMA1KD animals. (A, B) Xenografted animals were injected with luciferin and 
imaged. (A) Representative images of luciferase-positive parental and CARMA1KD CEM 
cells at week 2. (B) Quantitation of signal intensity (n=5 animals). P-values determined 
using 2-way ANOVA. (C) Lin
-
 cells from bone marrow of C57Bl/6 and CARMA1-/- were 
transfected with Notch1∆E-GFP and transferred into irradiated B6.LY5.1 animals. Organs 
specified were removed on day 35 post cell transfer and GFP
+
LY5.2
+
 cells enumerated 
from WT/WT
 Notch1∆E
 (WT-NOTCH1-∆E) and WT/CARMA1-/- Notch1∆E (CARMA1KO-
NOTCH1-∆E) animals. P-values shown used the Student’s t-test.  
Supplemental Figure 3: CARMA1 regulates T-ALL cell migration in vivo to the CNS. 
Heads of WT/WT
 Notch1∆E
 (WT-NOTCH1-∆E) or WT/CARMA1-/- Notch1∆E (CARMA1KO-
NOTCH1-∆E) were processed for H&E (in Methods). Images of sections through skull and 
meninges of two representative mice (of 4) and stained for H&E (left hand panel) or anti-
GFP (right hand panel). Meningeal infiltration indicated by thick arrow and bone marrow 
by *. Scale bar represents 100µm. 
Supplemental Figure 4: CARMA1 and CCR7-deficiency prolong survival in a mouse 
model of T-ALL similarly. Lin
-
 cells were purified from bone marrow of WT C57Bl/6, 
CARMA1-/-, or CCR7-/- animals, transfected with Notch1∆E-GFP, and transferred into 
lethally irradiated B6.LY5.1 animals. Survival curves for WT/WT
 Notch1∆E
 (WT; n=12), 
WT/CARMA1-/-
 Notch1∆E
 (CARMA1KO; n=11), or WT/CCR7-/-
 Notch1∆E
 (CCR7KO; n=10) 
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animals are shown. P-values between survival curves was determined using the Mantel-
Cox test. 
Supplemental Figure 5: CARMA1 colocalizes with CCR7. Parental CEM cells were 
transfected with CARMA1-GFP and CCR7-mCherry and imaged. Scale bar = 7µm.  
Supplemental Figure 6: PKCθ expression does not affect T-ALL disease in a xenograft 
model. (A) NSG recipients were xenografted with parental CEM or PKCθKD CEM cells. 
Survival curves of NSG mice receiving parental or PKCθKD CEM cells. Parental CEM: 
n=22; PKCθKD CEM: n=6. Comparison of survival curves showed p>0.05 was determined 
using the Mantel-Cox test. (B) Luciferase-positive parental and PKCθKD CEM cells at 
week 2 and 3 post cell transfer with quantitation of signal intensity (n=5 for each). The 
Student’s t-test showed p>0.05 when comparing intensity curves. 
Supplemental Table 1: CARMA1 regulates T-ALL cell accumulation in the CNS. (A) H&E 
sections from NSG mice xenografted with parental or CARMA1KD CEM cells were 
processed at indicated times and data for 2 animals shown. (B) H&E sections from 
B6.LY5.1 animals receiving WT Notch1∆E-GFP or CARMA1KO Notch1∆E-GFP 
transduced cells at week 5 post transfer and processed as described and analyzed for 4 
animals shown. 
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